Ideas with a route to responsible use
A medicines business creates value through more than a name. Software, research, publications, designs and know-how can each involve different rights, responsibilities and agreements. This page explains the categories relevant to NEUVIOR and the public trade-mark records checked for our principal names. It also provides a route for discussing permission, collaboration or a potential licence without exposing unpublished work or treating a broad ambition as a verified portfolio of exclusive rights.
Our principal UK word marks
The UK IPO register records NEUVIOR, number UK00004353863, as Registered, with entry in the register on 5 June 2026. The listed proprietor is NEUVIOR Pharmaceuticals Ltd, company number SC857853. The record includes classes 5, 9, 35 and 42 (IPO, 2026a). These class numbers are an introduction to the record; the actual scope depends on its specified goods and services.
The register also records PHARMORIS, number UK00004301201, as Registered, with entry on 20 February 2026. The listed proprietor is the same company. The record includes classes 9 and 42 (IPO, 2026b). Both records were checked on 13 October 2026. The links below lead to the official cases, where readers can inspect current status, ownership and the complete goods-and-services wording.
What a trade-mark record does and does not establish
These are UK word-mark records. They should not be read as claims that every logo, product name or slogan has been registered, or that the same protection exists in every country. A class listing is not a product authorisation or evidence that a described service is commercially available. Brand protection and the evidence needed to support a medicines or software proposition are separate questions.
Where you need to refer to NEUVIOR or PHARMORIS in a publication, partnership proposal or other context, explain the purpose and the material involved. A discussion about attribution is different from permission to present a logo as an endorsement. Co-branding, product incorporation and commercial licensing require a clear agreement appropriate to the intended use. This page does not grant a blanket right to reproduce or alter the identity.
Copyright and original material
UK copyright protection can arise automatically for qualifying original works, including software, web content, photography and written material; there is no UK register of copyright works (IPO, undated-a). The existence of a copyright notice does not mean NEUVIOR owns every image, source or quotation displayed here. Third-party publications, licensed footage, stock assets and open-source components retain their respective rights and applicable terms.
Ownership depends on how work was created and the relevant agreements. Commissioning material does not automatically transfer all copyright to the commissioner (IPO, 2014). A permission request should therefore identify the exact work, proposed use, territory, distribution and any adaptation. NEUVIOR would need to confirm which rights it controls before granting permission. Where rights belong elsewhere, the relevant owner or licence determines what may be done.
Research rights are specific to the work
Research can involve existing knowledge, new findings, data, materials, inventions and contributions from several people or institutions. Those categories should be addressed separately in the agreements governing a project. Funding, a research conversation or participation in a feasibility exercise does not by itself establish exclusive ownership of every output. A proposed commercial use needs a clear account of the relevant rights and any restrictions attached to them.
For a collaboration, the discussion should identify the background each party brings, the outputs expected, the rights needed to carry out the work and the arrangements for future use or publication. The IPO’s Lambert Toolkit illustrates different approaches to research collaboration, while noting its English-law basis (IPO, 2022). A suitable agreement still needs to reflect the actual project, organisations and jurisdiction.
Know-how and unpublished work
Some useful information is intentionally absent from public marketing pages. An interested party may be able to understand the buyer problem, evaluation question and development direction without seeing proprietary implementation detail or unpublished results. The IPO notes that making an invention public can affect the ability to seek patent protection (IPO, undated-b). Disclosure therefore needs an appropriate purpose and sequence rather than being driven by the desire to fill a website.
This page does not announce a granted patent, pending patent application or freedom-to-operate conclusion for a NEUVIOR programme. Those are specific claims requiring their own evidence. Where a legitimate discussion requires non-public material, the parties can consider confidentiality terms and a scoped disclosure. An NDA is not an assignment or a product licence; the rights required for research, evaluation or commercial use must be addressed separately.
A licensing discussion needs an identifiable use
A useful first note identifies what you want to use and why. That might concern reproduction of a publication, a brand permission, a defined research collaboration or exploration of an appropriately scoped commercial licence. Describe the intended field, territory, users and duration at a high level. There is no need to send confidential technical material simply to establish whether a conversation is relevant.
The next discussion would examine what rights are actually available, who controls them and what permissions or agreements the proposed use requires. Commercial terms, exclusivity, development responsibilities, publication and improvements would depend on the specific opportunity. This is an invitation to clarify a rights question, not a catalogue of transferable assets or a promise that any particular licence is available. Begin with the use you are considering, and we can assess the appropriate route.
References
Intellectual Property Office (2026a), NEUVIOR, UK00004353863. Official UK register case. Status, proprietor, classes and dates checked 13 October 2026.
Intellectual Property Office (2026b), PHARMORIS, UK00004301201. Official UK register case. Status, proprietor, classes and dates checked 13 October 2026.
Intellectual Property Office (undated-a), How copyright protects your work. Copyright overview. Checked 13 October 2026.
Intellectual Property Office (2014), Ownership of copyright works. Ownership guidance. Checked 13 October 2026.
Intellectual Property Office (2022), Lambert Toolkit. Collaboration and jurisdiction guidance. Checked 13 October 2026.
Intellectual Property Office (undated-b), Apply for a patent: before you apply. Official patent guidance. Checked 13 October 2026.
